Neurocrine Biosciences Inc (NBIX)

41.66
0.05 0.12
NASDAQ : Health Care
Prev Close 41.71
Open 42.17
Day Low/High 41.39 / 42.75
52 Wk Low/High 31.25 / 58.46
Volume 616.48K
Avg Volume 924.20K
Exchange NASDAQ
Shares Outstanding 86.87M
Market Cap 3.73B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference

Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference

Live Audio Webcast will be on November 30, 2016

Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference

Live Audio Webcast will be on November 16, 2016

Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference

Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference

Live Audio Webcast will be on November 7, 2016

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2016 Results

Conference Call and Webcast Scheduled For Wednesday, November 2, 2016

AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At The American Society For Reproductive Medicine Scientific Congress

AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At The American Society For Reproductive Medicine Scientific Congress

- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference

Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference

Live Audio Webcast will be on September 13, 2016

Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference

Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference

Live Audio Webcast will be on September 7, 2016

Neurocrine Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome

Neurocrine Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome

Six Month Open Label Safety and Tolerability Study of Valbenazine

Short Interest In Neurocrine Biosciences Jumps 14%

Short Interest In Neurocrine Biosciences Jumps 14%

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 606,250 share increase in total short interest for Neurocrine Biosciences, Inc. , to 4,930,434, an increase of 14.02% since 06/30/2016.

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results

Conference Call and Webcast Scheduled For Wednesday, August 3, 2016

Bearish Bets: Biotech, Energy and Other Stocks that Look Good to Short

NBIX, ZPIN, VLP, NWLI and INFO were all recently downgraded by TheStreet's Quant Ratings.

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ESNT, HBHC, HMY, IILG, MYCC, NEWM, PRTY, TOT, VTTI Downgrades: NBIX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Short Interest In Neurocrine Biosciences Decreases By 30%

Short Interest In Neurocrine Biosciences Decreases By 30%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 1,864,374 share decrease in total short interest for Neurocrine Biosciences, Inc. , to 4,324,184, a decrease of 30.13% since 06/15/2016.

Neurocrine Biosciences To Present At The Jefferies 2016 Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2016 Healthcare Conference

Live Audio Webcast will be on June 8, 2016

Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today

Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders

Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders

Stocks with insider trader activity include NBIX, FRGI and LBAI

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.

Strong On High Volume: Neurocrine Biosciences (NBIX)

Strong On High Volume: Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Short Interest Moves 11% Higher For NBIX

Short Interest Moves 11% Higher For NBIX

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 692,785 share increase in total short interest for Neurocrine Biosciences, Inc. , to 6,943,712, an increase of 11.08% since 04/15/2016.

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Live Audio Webcast will be on May 12, 2016